Glenmark Pharmaceuticals Ltd Q2FY26 – ₹60,469 mn Revenue, ₹23,596 mn EBITDA, $700M AbbVie Upfront: When a Pharma Stock Becomes a Plot Twist Machine

1. At a Glance

Imagine you’re watching a pharma thriller — one where the company starts the quarter with lawsuits, sells its subsidiary, then lands a $700 million licensing deal with AbbVie. Welcome to Glenmark Pharmaceuticals Ltd, where the medicine cabinet has more drama than Netflix.

As of November 2025, the company’s market cap stands at ₹51,944 crore, trading at ₹1,844/share, with a P/E of 20.7x — lower than the industry average of 31.1x. The latest Q2FY26 consolidated revenue came in at ₹60,469 million (₹6,046.9 crore), with EBITDA at ₹23,596 million (₹2,359.6 crore) and a profit surge that would make even Dr. Reddy’s Labs raise an eyebrow: quarterly profit of ₹1,535 crore, up 333% YoY.

Return on capital employed (ROCE) sits pretty at 19.4%, and the company recently declared an interim dividend of ₹2.50. Debt? Barely ₹1,224 crore, with a Debt-to-Equity ratio of 0.13, meaning Glenmark’s balance sheet has been hitting the gym.

In short: Glenmark’s fiscal story is that of a once-sleepy generics maker that turned into a global research-led chaos orchestra — with patents, divestments, and a Hollywood-level plot twist every quarter.

2. Introduction

If the Indian pharma industry were a Bollywood movie, Glenmark would be that underdog scientist who discovers a miracle drug, gets sued in the U.S., wins European approvals, and walks away richer than before — all in one song sequence.

Founded in 1977 and led by the Saldanha family, Glenmark is now a multinational beast with operations in 80+ countries, 14 manufacturing facilities, and an R&D budget that could finance a small Marvel movie — ₹916 crore spent in 9MFY24 alone.

The stock has been through its share of drama — from the dull, patent-losing generics era to a fresh new narrative built around respiratory, dermatology, and oncology. Its specialty drug RYALTRIS, now approved in over 70 countries, is the poster child of this transformation.

After divesting 75% of Glenmark Life Sciences to Nirma for ₹5,651 crore, the company freed up capital, fixed its debt metrics, and focused on innovation. The cherry on top? A $700 million upfront payment from AbbVie in September 2025 for ISB 2001, a bispecific antibody for cancer.

Who knew selling APIs to Nirma would finance a biotech dream?

3. Business Model – WTF Do They Even Do?

Glenmark runs a three-pronged business model — kind of like a balanced Indian thali: some generic rice, spicy specialty curries, and a research dessert.

a) Generics:
The bread-and-butter business that sells affordable versions of branded drugs across markets like the U.S., India, and Europe. This segment includes oral solids, injectables, and inhalers. It’s a stable cash generator — a pharmaceutical comfort food, if you will.

b) Specialty & OTC:
The fancy side of Glenmark — where products like RYALTRIS (for allergic rhinitis) and Lirafit (India’s first biosimilar of liraglutide) steal the show. Specialty now accounts for a growing chunk of revenue, and RYALTRIS alone has been commercialized in 31 countries with approvals in 18 more.

c) Innovation via Ichnos Sciences (USA):
The mad scientist lab of the group. Focused on biologics and oncology, Ichnos is where molecules like ISB 2001 were born — later monetized in blockbuster deals like the AbbVie $700M upfront + milestone potential.

The reorganization split Glenmark into three clear entities:

1. Glenmark Pharmaceuticals Ltd – global generics & specialty business.
2. Ichnos Sciences Inc. – U.S.-based biotech innovation arm.
3. Glenmark Consumer Care Ltd. – OTC & personal care spin-off.

Basically, it’s like Glenmark cloned itself into three, and now all three are doing their own corporate PhDs.

4. Financials Overview

Commentary:
The numbers look less like a pharma statement and more like a crypto bull run. Revenue almost doubled, PAT quadrupled, and EBITDA margin touched 39%, thanks to the AbbVie licensing